missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-c-Cbl (Tyr700) Recombinant Rabbit Monoclonal Antibody (CblY700-E1), APC, Invitrogen™
Rabbit Recombinant Monoclonal Antibody
Marca: Invitrogen™ MA537353
Este artículo no se puede devolver.
Vea la política de devoluciones
Descripción
Cbl proteins are a family of ubiquitin protein ligases (E3s) that negatively regulate signaling by targeting activated tyrosine kinases for degradation. Cbl- c is the most recently cloned member of the Cbl proteins and is expressed only in epithelial cells (the other Cbl proteins are ubiquitously expressed). Cbl-c, like the other mammalian Cbl proteins, can ubiquitinate the activated EGFR and target it for degradation. Through interactions with proteins containing SRC homology-2 (SH2) and SH3 domains, CBL proteins modulate downstream cell signaling.
Especificaciones
| Phospho-c-Cbl (Tyr700) | |
| Recombinant Monoclonal | |
| APC | |
| Cbl | |
| 4732447J05Rik; Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B-lineage lymphoma; casitas B-lineage lymphoma proto-oncogene; CBL; Cbl proto-oncogene; Cbl proto-oncogene, E3 ubiquitin protein ligase; CBL2; Cbl-2; CBL-3; CBLC; c-Cbl; E3 ubiquitin-protein ligase CBL; FRA11B; fragile site, folic acid type, rare, fra(11)(q23.3); NSLL; oncogene CBL2; proto-oncogene c-Cbl; RGD1561386; RING finger protein 55; RING-type E3 ubiquitin transferase CBL; RNF55; RNF57; signal transduction protein CBL | |
| Rabbit | |
| Protein A/G | |
| RUO | |
| 12402, 500985, 867 | |
| 4°C | |
| Liquid |
| Flow Cytometry | |
| CblY700-E1 | |
| PBS with 0.20% BSA and 0.09% sodium azide | |
| P22681, P22682 | |
| Cbl | |
| A synthetic phospho-peptide corresponding to residues surrounding Tyr700 of human phospho c-Cbl. | |
| 10 Tests | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG κ |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido